Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22504168 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL14814362 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL21518920 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL29093223 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL14749827 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL14814315 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL29092737 | 1.00 | BTK (0.49) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL25905000 | 0.92 | BTK (0.43) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL14750099 | 0.90 | BTK (0.56) | BTKKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL14814113 | 0.90 | BTK (0.56) | BTKKMT2AMEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174646-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4342466-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-111902408-B | Heteroaryl substituted pyrazole compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| CN-111757877-B | Methyllactam ring compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-10-27 | — | — | CN | disclosed |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | JAPAN TOBACCO INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | JAPAN TOBACCO INC. (JP) | 2023-04-20 | — | — | US | disclosed |
| EP-4026564-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026562-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | Japan Tobacco Inc. (JP) | 2022-07-13 | — | — | EP | disclosed |
| CN-114641314-A | Method for treating or preventing chronic kidney disease | 日本烟草产业株式会社 | 2022-06-17 | — | — | CN | disclosed |
| CN-114585387-A | Method for treating or preventing diabetes by using combined medicine | 日本烟草产业株式会社 | 2022-06-03 | — | — | CN | disclosed |
| US-11014910-B2 | Methyllactam ring compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-10988462-B2 | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2021-04-27 | — | — | US | disclosed |
| WO-2021045161-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | 日本たばこ産業株式会社 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021045159-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | 日本たばこ産業株式会社 | 2021-03-11 | — | — | WO | disclosed |
| EP-3778593-A1 | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3760624-A1 | METHYLLACTAM RING COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111902408-A | Heteroaryl-substituted pyrazole compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2020-11-06 | — | — | CN | disclosed |
| CN-111757877-A | Methylolactam ring compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2020-10-09 | — | — | CN | disclosed |
| US-20190352284-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
| US-20190330193-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988462-B2 | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | SLC5A1, SLC5A2, SULT2A1 | BTK 4080/4885KMT2A 1814/4885MEN1 3437/4885 |
| US-20190330193-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SULT2A1 | BTK 4080/4885KMT2A 1814/4885MEN1 3437/4885 |
| US-11014910-B2 | Methyllactam ring compound and pharmaceutical use thereof | SLC5A1, SLC5A2, SLC5A6 | BTK 1609/4885KMT2A 236/4885MEN1 951/4885 |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | SLC5A1, SLC5A2, REN | BTK 2709/4885KMT2A 1249/4885MEN1 4016/4885 |
| US-20240174646-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC5A6 | BTK 1609/4885KMT2A 236/4885MEN1 951/4885 |
| US-20190352284-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC5A6 | BTK 1609/4885KMT2A 236/4885MEN1 951/4885 |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | DPP4, SLC5A1, SLC5A2 | BTK 4261/4885KMT2A 2083/4885MEN1 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.